Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body.
OMICS International organised 21 Conferences/Workshops, 3 Symposium, 2 Papers Published, with 13 Speakers till date .
OMICS International Organizes 300+ conferences, 500+workshops and 200+symposiums on Clinical, Medicine, Pharma, Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more Scientific Societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members. The OMICS International Conferences are instrumental in giving a serious stage to the incredibly famous scientists, understudies, researchers, academicians, organizations, business visionaries and businesses through its 300+ International Conferences and occasions yearly all through the globe to raise and examine the advancements in the field of OMICS Study. OMICS International Conferences are completely pressed with intriguing occasions, exercises and learning going with the quick entrepreneurial enthusiasm to make them genuine. They are multidimensional with synchronous movement situated symposia, International workshops and presentations where the identities from Sciences (Both unadulterated & connected), Pharmaceutical, Medical, Clinical, Engineering & Technology and Life Sciences accumulate with their procedures in discovering genuine answers for different basic issues around the globe.
Scope & Importance
Cancer biomarkers can a offer value in predicting or monitoring cancer recurrence. The Oncotype DX® breast cancer assay is one such test used to predict the likelihood of breast cancer recurrence. Thist test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy. Oncotype DX looks at a panel of 21 genes in cells taken during tumor biopsy. The results of the test are given in the form of a recurrence score that indicates likelihood of recurrence at 10 years.
Cancer Biomarker is concerned with:
· Biomarker should be involved in process that causes the cancer
· Changes in biomarker should correlate with changes in the disease
· Levels of biomarkers should be high enough that they can be measured easily and reliably
·Levels or presence of biomarker should readily distinguish between normal, cancerous, and precancerous tissue
·Effective treatment of the cancer should change the level of the biomarker
·Level of the biomarker should not change spontaneously or in response to other factors not related to the successful treatment of the cancer
Cancer Biomarker is a major participant in any multi-disciplinary team (MDT), which would meet regularly to discuss site specific cases of tumours. Other members would be site specific surgeon, palliative care physician, radiologist, pathologist, specialist nursing staff and appropriate haematologist and medical oncologist.
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia).
The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. The biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.
Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period.
List of International Conferences on Oncology
List of major Associations and Societies on Oncology
List of Key Companies
This page will be updated regularly.
This page was last updated on October 22, 2021